The Glycemia Risk Index (GRI) as a Biomarker for Subclinical Endothelial Dysfunction in Type 1 Diabetes: A...

Area of Science:

• Endocrinology
• Cardiovascular Research
• Diabetes Management

Background:

• Endothelial progenitor cells (EPCs) are crucial for maintaining healthy blood vessels.
• Reduced EPC levels are common in type 1 diabetes (T1D) and linked to endothelial dysfunction.
• The Glycemia Risk Index (GRI) measures glucose control quality, encompassing both high and low blood sugar risks.

Purpose of the Study:

• To examine the relationship between the Glycemia Risk Index (GRI) and circulating EPC levels in adults with T1D.
• To determine if GRI can serve as a biomarker for cardiovascular risk in T1D.

Main Methods:

• A cross-sectional study involving 132 adults with T1D on intensive insulin therapy.
• GRI was calculated using 14-day continuous glucose monitoring data.
• EPCs (CD34+, CD133+, KDR+, CD34+KDR+) were quantified via flow cytometry.

Main Results:

• Higher GRI scores were associated with poorer metabolic health indicators.
• Participants with higher GRI had significantly lower counts of CD34+, CD133+, KDR+, and CD34+KDR+ cells.
• A negative association was observed between GRI and CD34+, CD34+CD133+, and CD34+KDR+ cell counts.
• No significant link was found between HbA1c and EPC phenotypes.

Conclusions:

• Adults with T1D and high GRI levels exhibit reduced EPC counts.
• GRI is significantly associated with specific EPC phenotypes, indicating its potential as a cardiovascular risk biomarker in T1D.
• GRI may offer a more comprehensive assessment of diabetes-related cardiovascular risk than HbA1c alone.